Cell Markers
Using samples from your blood and bone marrow tests, the pathology department should also carry out special tests (called immunophenotyping) on the lymphocytes found in the samples. These tests look for special proteins (antigens), known as markers, on the surface of the cells. Different types of cancer cells have their own special sets of markers.3,8-10
Some pathology departments also carry out cytogenetic testing, such as fluorescence in situ hybridization (FISH) tests, where they look for any changes to the chromosomes in the lymphocytes. These help to ensure an accurate diagnosis and give an idea of how fast the disease is likely to progress.4,8-10
Typical markers on a B-CLL cell10,13
Together, your blood and bone marrow tests are used to show3,8-10:
- Whether the lymphocytes are associated with CLL
- Whether the lymphocytes involved are type B (most common), T, or NK. T-cell type CLL, although more rare, progresses more rapidly than B-cell type and more often affects the skin, nerves, and lymph nodes
- Whether you have anemia or thrombocytopenia
- What effect the disease is having on levels of gamma globulins, the antibodies produced by the B cells that are important in fighting infection
Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS
Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].
Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].
Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].
The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.
Please see Full Prescribing Information (PDF).